Taisei Keitoku
YOU?
Author Swipe
View article: Clinical outcome of radiofrequency ablation in patients with hepatocellular carcinoma aged 80 years and older
Clinical outcome of radiofrequency ablation in patients with hepatocellular carcinoma aged 80 years and older Open
Background and aim The incidence of hepatocellular carcinoma (HCC) is positively correlated with age, and the population of patients with HCC was also older at the time of clinical diagnosis. In the SURF trial, elderly people aged ≥80 year…
View article: Magnetic resonance elastography for the prediction of hepatocellular carcinoma in chronic hepatitis B
Magnetic resonance elastography for the prediction of hepatocellular carcinoma in chronic hepatitis B Open
Background and Aim Magnetic resonance elastography (MRE) is used for the evaluation of liver fibrosis; however, it remains unclear whether MRE‐based liver stiffness is associated with hepatocellular carcinoma (HCC) development, particularl…
View article: 975P The clinical impact of urinary protein creatinine ratio and AFP at six weeks in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
975P The clinical impact of urinary protein creatinine ratio and AFP at six weeks in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab Open
View article: A Comparison of Alanine Aminotransferase Normalization between Pemafibrate and Bezafibrate in Patients with Nonalcoholic Fatty Liver Disease
A Comparison of Alanine Aminotransferase Normalization between Pemafibrate and Bezafibrate in Patients with Nonalcoholic Fatty Liver Disease Open
Objective Pemafibrate is a recently developed selective peroxisome proliferator-activated receptor alpha modulator that can improve alanine aminotransferase (ALT) levels in patients with nonalcoholic fatty liver disease (NAFLD). However, t…
View article: Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis B
Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis B Open
Background and Aim Hepatocellular carcinoma development can be decreased by achieving and maintaining complete virological response (CVR) in chronic hepatitis B. However, it is unclear whether switching from entecavir (ETV) to tenofovir al…
View article: Pemigatinib treatment for intrahepatic cholangiocarcinoma with <scp>FGFR2</scp> fusion detected by a liquid comprehensive genomic profiling test
Pemigatinib treatment for intrahepatic cholangiocarcinoma with <span>FGFR2</span> fusion detected by a liquid comprehensive genomic profiling test Open
Key Clinical Message The liquid CGP was useful for detecting FGFR2 fusion and the patient experienced typical side effects (nail disorders, hyperphosphatemia, and taste disorders) of pemigatinib that required treatment.
View article: Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease
Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease Open
Background Patients with nonalcoholic fatty liver disease (NAFLD) are highly at risk for cardiovascular disease (CVD). However, the risk of developing CVD in patients with lean NAFLD is not yet fully understood. Therefore, this study aimed…
View article: Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test
Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test Open
Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling testShun Ishido¹*, Nobuharu Tamaki¹*, Kento Inada¹, Jun Itakura¹, Yuka Takahashi¹, Naoki Uchihara¹, Keito Suzu…
View article: Two Cases of Immune-Related ACTH Deficiency after the Initiation of Atezolizumab plus Bevacizumab for Multiple Hepatocellular Carcinoma
Two Cases of Immune-Related ACTH Deficiency after the Initiation of Atezolizumab plus Bevacizumab for Multiple Hepatocellular Carcinoma Open
Background: There have been a few case reports of immune-related Adrenocorticotropic Hormone (ACTH) deficiency in cases of atezolizumab plus bevacizumab therapy for unresectable HCC.Our report aims to enhance comprehension of immune-relate…
View article: Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease
Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease Open
Background: Patients with nonalcoholic fatty liver disease (NAFLD) are highly at risk for cardiovascular disease (CVD). However, the risk of developing CVD in patients with lean NAFLD is not yet fully understood. Therefore, this study aime…
View article: Clinical Utility of Comprehensive Genomic Profiling in Patients with Unresectable Hepatocellular Carcinoma
Clinical Utility of Comprehensive Genomic Profiling in Patients with Unresectable Hepatocellular Carcinoma Open
This study aimed to investigate the clinical usefulness of comprehensive genomic profiling (CGP) in patients with unresectable hepatocellular carcinoma who received multiple systemic therapies in real-world practice. In this study, all nin…
View article: Placebo Adverse Events in Non-alcoholic Steatohepatitis Clinical Trials: A Pooled Analysis of 2,944 Participants
Placebo Adverse Events in Non-alcoholic Steatohepatitis Clinical Trials: A Pooled Analysis of 2,944 Participants Open
INTRODUCTION: In the absence of an effective treatment for non-alcoholic steatohepatitis (NASH), a randomized, placebo-controlled trial (RCT) remains the current gold standard study design in NASH. As NASH is a largely asymptomatic disease…
View article: Global prevalence of depression and anxiety in patients with hepatocellular carcinoma: Systematic review and meta-analysis
Global prevalence of depression and anxiety in patients with hepatocellular carcinoma: Systematic review and meta-analysis Open
Background/Aims: Depression and anxiety are associated with poorer outcomes in patients with hepatocellular carcinoma (HCC). However, the prevalence of depression and anxiety in HCC are unclear. We aimed to establish the prevalence of depr…
View article: Clinical Usefulness of Monitoring Muscle Volume during Atezolizumab Plus Bevacizumab Therapy in Patients with Unresectable Hepatocellular Carcinoma
Clinical Usefulness of Monitoring Muscle Volume during Atezolizumab Plus Bevacizumab Therapy in Patients with Unresectable Hepatocellular Carcinoma Open
Background: Sarcopenia is associated with overall survival in patients with hepatocellular carcinoma (HCC). However, it is not known whether muscle volume is associated with clinical outcomes during combination therapy with immune checkpoi…